Home About us Contact | |||
Scientific Sessions (scientific + session)
Selected AbstractsSeventh Americas Hepatopancreatobiliary Congress ANNUAL SCIENTIFIC SESSION & POST GRADUATE PROGRAM April 19,22, 2007 Bally's Hotel Las Vegas, NevadaHPB, Issue 2007Article first published online: 17 FEB 200 First page of article [source] A proposal to redefine familial combined hyperlipidaemia , Third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the Scientific Sessions of the European Society for Clinical InvestigationEUROPEAN JOURNAL OF CLINICAL INVESTIGATION, Issue 2 2002A. D. Sniderman No abstract is available for this article. [source] 21st Annual Scientific SessionsPACING AND CLINICAL ELECTROPHYSIOLOGY, Issue 4 2000Article first published online: 28 JUN 200 First page of article [source] 63rd Scientific Sessions of the American Diabetes AssociationPRACTICAL DIABETES INTERNATIONAL (INCORPORATING CARDIABETES), Issue 1 2004Article first published online: 1 MAR 200 No abstract is available for this article. [source] Current issues for nurse practitioners: HyponatremiaJOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS, Issue 11 2007Ruth Haskal NP-C (Adult Nurse Practitioner) Abstract Purpose: To review the assessment, diagnosis, and management of hyponatremia (serum sodium <135 mEq/L), the most common electrolyte disturbance as a result of dysregulation of water balance in hospitalized or institutionalized patients. Data sources: Comprehensive search using keywords AVP receptor antagonists, hyponatremia, SIADH, conivaptan, tolvaptan, lixivaptan, nurse practitioner, and others was carried out using the National Library of Medicine (PubMed) Web site from which full-text articles were obtained. Meeting abstracts were obtained from scientific sessions including the American Society of Nephrology Renal Week 2004 and the Endocrine Society,s 87th Annual Meeting (2005). The Vaprisol (conivaptan hydrochloride injection) package insert was referenced and obtained from FDA.gov. Conclusions: A diagnosis of hyponatremia requires thorough investigation for underlying causes and prompt treatment to prevent poor patient outcomes. In clinical trials, a new class of drugs called the arginine vasopressin (AVP) receptor antagonists or aquaretics has been shown to be safe and effective for the treatment of hyponatremia. Among this class of agents, intravenous conivaptan hydrochloride, indicated for the treatment of euvolemic hyponatremia in hospitalized patients, is the first drug in class approved for use. Implications for practice: Elderly patients, and those with certain conditions such as heart failure, tuberculosis, cirrhosis, and head injury, may be at increased risk for hyponatremia. In hospitalized patients following surgery and the use of certain medications, hyponatremia is a common condition. A thorough understanding of the physiology of water balance and the risk factors associated with hyponatremia is essential for prompt and effective intervention. Awareness of the limitations of conventional therapies and the availability of new treatment options for hyponatremia allows clinicians to optimize patient care. [source] |